Physician profile
Daran L Parham
NPI 1285749499
$5,059.92
in general payments reported to CMS, 2019-2025
29 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $687 · 2021: $1,196 · 2022: $792 · 2023: $878 · 2024: $486 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,622.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,550.39 | 2019-2023 | |
| Therapeuticsmd, INC. | $361.48 | 2019-2022 | |
| Evofem Biosciences, INC. | $331.90 | 2020-2022 | |
| Exeltis, USA INC. | $305.89 | 2019-2024 | Tyblume, Slynd |
| Organon LLC | $278.13 | 2021-2025 | Nexplanon |
| Agile Therapeutics, INC. | $228.65 | 2021-2024 | Twirla |
| Millicent US INC | $228.01 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Pfizer INC. | $206.01 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $191.36 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $150.35 | 2021-2025 | |
| Astellas Pharma US INC | $138.77 | 2023-2025 | Veozah, Myrbetriq |
| Myovant Sciences INC. | $137.35 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $135.10 | 2019-2021 | |
| Roche Diagnostics Corporation | $103.80 | 2019-2021 | |
| Hologic Sales and Service, LLC | $95.58 | 2019-2024 | Aptima, Thinprep 2000 Processor, Fluent Fluid Management System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $93.20 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.85 | 2019-2024 | |
| Lupin INC. | $87.36 | 2019-2020 | |
| Sage Therapeutics, LLC | $77.59 | 2024-2025 | Zurzuvae |
| Mission Pharmacal Company | $56.15 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $54.07 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $27.76 | 2024 | |
| Tersera Therapeutics LLC | $25.16 | 2023 | Zoladex |
| Medtronic, INC. | $24.38 | 2023 | Truclear |
| Dexcom, INC. | $21.70 | 2025 | Dexcom G6 Transmitter |
| Mallinckrodt Enterprises LLC | $16.27 | 2019 | |
| Mallinckrodt Hospital Products INC. | $15.54 | 2020 | |
| Avion Pharmaceuticals | $14.73 | 2019 | |
| Exact Sciences Corporation | $13.39 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daran Parham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.